Detalhe da pesquisa
1.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
2.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
3.
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Diabetes Obes Metab
; 24(2): 187-195, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605142
4.
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
Diabetes Obes Metab
; 24(2): 196-203, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595812
5.
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(8): 1071-1077, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28191913
6.
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1521-1528, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28371155
7.
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.
J Diabetes Sci Technol
; 17(2): 274-282, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36575993
8.
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Lancet Diabetes Endocrinol
; 11(3): 158-168, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758572
9.
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Diabetes Care
; 46(5): 1052-1059, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36920867
10.
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Diabetes Care
; 46(5): 1060-1067, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944059
11.
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Hepatol Commun
; 2(5): 561-570, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29761171
12.
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
J Diabetes Complications
; 20(3): 145-52, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16632233
13.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes Care
; 39(7): 1241-9, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26681715
14.
Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes.
J Diabetes Complications
; 19(3): 128-32, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15866056
15.
Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes.
Acta Diabetol
; 50(1): 39-45, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21861172
16.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 40(6): 808, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28420698
17.
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 39(11): e199-e200, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27926898
18.
The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro.
J Diabetes Sci Technol
; 1(6): 929-35, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19885168